Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 1, 2019--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--
-
Mar 27, 2019
-
Feb 22, 2019--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018--
-
Jan 4, 2019-ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the Fourth Quarter of 2018-
-
Nov 8, 2018—Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director—
-
Nov 6, 2018
-
Oct 30, 2018—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch—
-
Oct 4, 2018New Patent Adds 7 ½ Years of Market Exclusivity in Japan
-
Oct 1, 2018
-
Sep 28, 2018Commercial availability expected in early Q4 2018
-
Sep 17, 2018As previously reported, study met primary endpoint of culture conversion (p<0.0001)
-
Aug 27, 2018Advisory committee supports surrogate endpoint of sputum culture conversion
-
Aug 2, 2018PDUFA (Prescription Drug User Fee Act) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for September 28, 2018
-
Jun 15, 2018Meeting planned for August 7, 2018
-
Jun 7, 2018